Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy

The characterization of hepatitis B virus (HBV) quasispecies in different compartments in liver transplant (LT) recipients may be helpful in optimizing prophylaxis regimens. The aims of this study were to evaluate liver, peripheral blood mononuclear cells (PBMC), and plasma samples for HBV and to compare the quasispecies in hepatic and extrahepatic sites in LT recipients on long‐term prophylaxis. For 12 patients followed for up to 15 years post‐LT, liver, plasma, and PBMC samples [all HBV DNA–negative according to conventional polymerase chain reaction (PCR) assays] were evaluated for HBV DNA by a sensitive nested PCR method [covalently closed circular DNA (cccDNA) for liver and PBMC samples] and by the sequencing and phylogenetic analysis of polymerase quasispecies. For the 10 patients on prophylaxis with no clinical recurrence (median time post‐LT = 15.5 months, range = 12‐96 months), liver samples were HBV DNA–reactive in 9 of 10 cases, plasma samples were HBV DNA–reactive in 3 of 10 cases, and PBMC samples were HBV DNA–reactive in 2 of 7 cases (including 1 case with HBV cccDNA in PBMCs). The sequence analysis showed that all HBV clones had a wild‐type (WT) sequence in the liver and PBMCs. In 2 patients with early HBV recurrence post‐LT who were treated with nucleosides only, HBV DNA was detected in serum, PBMC, and liver samples, and HBV cccDNA was found in liver samples. An HBV lamivudine‐resistant variant with an M204I mutation was identified in liver (70% and 18% of the clones) and plasma samples (100% of the clones), but a WT sequence was found in 70% and 100% of the PBMC clones. In conclusion, despite prophylaxis and the absence of HBV DNA in serum according to conventional assays, HBV is detectable in the serum, liver, and PBMCs of almost all patients, and this supports the use of continued anti‐HBV therapy in this group. Antiviral drug–resistant variants are more frequent in the liver versus PBMCs, but both compartments are potential sources of reinfection. Liver Transpl 17:955–962, 2011. © 2011 AASLD.

[1]  J. Roberts,et al.  Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy , 2011, Journal of viral hepatitis.

[2]  D. Samuel,et al.  Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. , 1997, Journal of hepatology.

[3]  T. Michalak,et al.  In Vitro and In Vivo Infectivity and Pathogenicity of the Lymphoid Cell-Derived Woodchuck Hepatitis Virus , 2001, Journal of Virology.

[4]  Tomasz P. Michalak,et al.  Persistence of infectious hepadnavirus in the offspring of woodchuck mothers recovered from viral hepatitis. , 1999, The Journal of clinical investigation.

[5]  J. Jang,et al.  Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine‐resistant hepatitis B virus during adefovir therapy , 2007, Journal of medical virology.

[6]  S. Papson,et al.  “Model” , 1981 .

[7]  S. Locarnini.  Hepatitis B virus surface antigen and polymerase gene variants: Potential virological and clinical significance , 1998, Hepatology.

[8]  Tomasz P. Michalak,et al.  Persistence of isolated antibodies to woodchuck hepatitis virus core antigen is indicative of occult infection , 2004, Hepatology.

[9]  M. Manns,et al.  Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. , 2001, Journal of hepatology.

[10]  C. Coffin,et al.  Low doses of hepadnavirus induce infection of the lymphatic system that does not engage the liver. , 2004, Journal of virology.

[11]  Ding‐Shinn Chen,et al.  Distinct Hepatitis B Virus Dynamics in the Immunotolerant and Early Immunoclearance Phases , 2010, Journal of Virology.

[12]  F. Zoulim,et al.  In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. , 2009, Gastroenterology.

[13]  M. Rizzetto,et al.  Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[14]  T. Liang,et al.  Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[15]  A. Lok,et al.  Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[16]  Tomasz P. Michalak,et al.  Profound suppression of chronic hepatitis C following superinfection with hepatitis B virus , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[17]  M. Ciotti,et al.  Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. , 2011, Journal of hepatology.

[18]  Mark J. Thomas,et al.  Combination Therapy in Liver Transplant Recipients with Hepatitis B Virus Without Hepatitis B Immune Globulin , 2007, Digestive Diseases and Sciences.

[19]  Nidhi Singh,et al.  Management of hepatitis B virus. , 2008, The Journal of antimicrobial chemotherapy.

[20]  S. Locarnini.  Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure , 2008, Hepatology international.

[21]  K. Man,et al.  Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[22]  G. Alexander,et al.  Liver transplantation in European patients with the hepatitis B surface antigen. , 1993, The New England journal of medicine.

[23]  D. Samuel,et al.  HBV DNA persistence 10 years after liver transplantation despite successful anti‐HBS passive immunoprophylaxis , 2003, Hepatology.

[24]  P. Coursaget,et al.  Genetic Diversity of Hepatitis B Virus Strains Derived Worldwide: Genotypes, Subgenotypes, and HBsAg Subtypes , 2004, Intervirology.

[25]  N. Terrault,et al.  Hepatitis B immune globulin preparations and use in liver transplantation. , 2003, Clinics in liver disease.

[26]  D. Samuel,et al.  Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. , 1990, Transplantation.

[27]  M. Buti,et al.  A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. , 2003, Journal of hepatology.

[28]  S. Gujar,et al.  Primary Occult Hepadnavirus Infection Induces Virus-Specific T-Cell and Aberrant Cytokine Responses in the Absence of Antiviral Antibody Reactivity in the Woodchuck Model of Hepatitis B Virus Infection , 2009, Journal of Virology.

[29]  D. Samuel,et al.  Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.